Leukotriene Synthesis Inhibitors of the Quinoline Type: Parameters for the Optimization of Efficacy
- 1 January 1995
- journal article
- Published by Elsevier BV in European Journal of Medicinal Chemistry
- Vol. 30, 441s-451s
- https://doi.org/10.1016/s0223-5234(23)00143-5
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- The binding of leukotriene biosynthesis inhibitors to site-directed mutants of human 5-lipoxygenase-activating proteinLife Sciences, 1994
- Role of 5-lipoxygenase-activating protein in the regulation of 5-lipoxygenase activity in human neutrophilsInflammation Research, 1994
- Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005European Journal of Pharmacology, 1994
- 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes.The Journal of Experimental Medicine, 1993
- 5‐Lipoxygenase‐activating protein stimulates the utilization of arachidonic acid by 5‐lipoxygenaseEuropean Journal of Biochemistry, 1993
- 5‐lipoxygenase‐activating protein is an arachidonate binding proteinFEBS Letters, 1993
- In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesisInflammation Research, 1993
- 5-Lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitorsJournal of Medicinal Chemistry, 1992
- Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interactions with biological membranesJournal of Medicinal Chemistry, 1991
- Leukotrienes and Other Products of the 5-Lipoxygenase PathwayNew England Journal of Medicine, 1990